Researchers found that a new gene therapy called PST-611 may offer hope for people suffering from late-stage dry age-related macular degeneration (AMD), specifically a type known as geographic atrophy (GA). This condition affects millions worldwide and can lead to permanent vision loss, severely impacting daily activities like reading and driving. In a small clinical trial, PST-611 showed an excellent safety profile and even early signs of improving vision in some participants after just one dose.

This discovery is significant for anyone concerned about eye health and aging. With AMD being a leading cause of vision impairment in older adults, effective treatments are urgently needed. The Phase 1 trial involved six patients and monitored them over 16 weeks. While the primary goal was to assess safety, participants reported improvements in their vision, indicating that PST-611 could potentially slow down or halt the progression of GA.

The research is still in its early stages, with these promising results coming from a small human trial. More extensive testing is planned, including a Phase 2a trial to further evaluate the safety and efficacy of multiple doses over a year. While these findings are encouraging, they are not yet conclusive, and more research is needed to confirm PST-611’s effectiveness in a larger group of patients.

For those interested in maintaining their vision as they age, staying informed about advancements in AMD treatments like PST-611 could be beneficial. If you or someone you know is at risk for AMD, consider discussing these developments with a healthcare professional to understand potential options and ongoing research in the field.

Source: globenewswire.com